Tests targeted radiation for prostate cancer spread that keeps growing on treatment
Tests targeted radiation alongside current hormone therapy in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06927635, who can take part
Where in Canada
- Princess Margaret Cancer CenterToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT06927635
- Record updated
- 7 July 2026
- Original description
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).Read full original descriptionShow less
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Inclusion: Age >18 years; Able to provide informed consent; Histologic diagnosis of prostate adenocarcinoma; Castrate Resistance Prostate Cancer; Radiographic evidence of <10 sites of extra-cranial OP metastatic lesions; Receiving any line of ST for >3 months; All sites of OP disease are amenable to and can be safely treated with SBRT; ECOG performance status 0-3.
Exclusion: Contraindication to radiotherapy; Evidence of spinal cord compression.